PMVP.US Pmv Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
1.22 USD
Close of Nov 18, 2026
1.02 1.91
Market cap
USD 92.2M
P/E
-
P/B
1.57x
ROE
-164.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PMVP.US undervalued?

Graham number

The Graham number of Pmv Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pmv Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Pmv Pharmaceuticals Inc yet.

Pmv Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pmv Pharmaceuticals Inc

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceutical…

Full company profile